New treatment?
|
From: himself on 21 Jul 2008 19:27 http://news.bbc.co.uk/1/hi/health/7502238.stm You may already know of this, but I just came across it. -- Rog
From: kh on 21 Jul 2008 20:19 On Jul 21, 7:27 pm, "himself" <ber...(a)hotmail.com> wrote: > http://news.bbc.co.uk/1/hi/health/7502238.stm > You may already know of this, but I just came across it. > -- > Rog Thanks Rog. That does sound promising. "British researchers have made a dramatic breakthrough against a lethal form of prostate cancer." "Trials of a new pill have shown that it can shrink tumours in up to 80 per cent of cases, and end the need for damaging chemotherapy and radiotherapy." "Experts hailed the advance as potentially the biggest in the field of prostate cancer for decades, capable of saving many thousands of lives." "The drug, abiraterone, was discovered by researchers at the Royal Marsden Hospital in South-West London." "Abiraterone uses a different approach, blocking chemicals in the body which help in the production of the male hormones. It is expected to be widely available in three years, but until then can be obtained only as part of clinical trials." Already available in clinical trials, this is good day. -kh
From: J on 22 Jul 2008 01:26 himself wrote: > http://news.bbc.co.uk/1/hi/health/7502238.stm > You may already know of this, but I just came across it. > http://www.medicalnewstoday.com/articles/97606.php Prostate / Prostate Cancer News Useful Links Video Library Preliminary Phase II Results Of Abiraterone Acetate In Patients With Castration-resistant Metastatic Prostate Cancer Main Category: Prostate / Prostate Cancer Also Included In: Clinical Trials / Drug Trials Article Date: 17 Feb 2008 - 0:00 PDT email icon email to a friend printer icon printer friendly write icon view / write opinions rate icon rate article Ads by Google PSA Levels Truth The Truth Your Doctor Won't Tell You, Read About Prostate Cancer Now ProstateTruth.com Prostate Cancer Treatment Your Prostate Cancer Solution. See Results. Request Info Today! www.InternationalHIFU.com Current Article Ratings: Patient / Public: 4 and a half stars 4.5 (4 votes) Health Professional: not yet rated Article Opinions: 0 posts UroToday.com - Dr. Danila, spoke about abiraterone acetate (AA), an oral and irreversible inhibitor of CYP17 that decreases testosterone and DHT levels to undetectable. The study presented sought to determine the proportion of patients achieving a PSA decline of >50% and to assess toxicity. It was a multicenter trial using AA 1000mg orally daily and prednisone 5mg daily. Successful AA activity was defined as a PSA decline >50% in >30% of patients. It was not successful if the PSA decline occurs in <10% of patients. 44% met the criteria of >50% PSA decline. Radiological assessment was possible in 26 men who had at least 3 cycles of treatment. No decreases in bone metastasis by bone scans were noted, but some had unchanged bone scans. The addition of prednisone reduced the frequency of adverse events. Circulating tumor cells (CTCs) was used as an additional means to asses response to treatment and did correlate with PSA changes. A total of >5 CTCs prior to treatment that decreased to <3 CTCs correlated with response. To date, 13 of 38 patients continue on therapy. A phase III trial is planned to compare AA and prednisone to placebo and prednisone. Presented by D.C. Danila at the American Society of Clinical Oncology (ASCO) - 2008 Genitourinary Cancers Symposium - A Multidisciplinary Approach - February 14-16, 2008 San Francisco, California, USA Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS Professor & Chairman Department of Urology University of California, Davis, School of Medicine Sacramento, CA http://en.wikipedia.org/wiki/Abiraterone Abiraterone is currently a drug under investigation for use in prostate cancer. It blocks the formation of testosterone by inhibiting CYP17A1 (CYP450c17), an enzyme also known as 17a-hydroxylase/17,20 lyase.[1] This enzyme is involved in the formation of DHEA and androstenedione, which may ultimately be metabolized into testosterone. The results of two Phase II trials indicate that abiraterone may reduce prostate specific antigen (PSA) levels, as well as shrink tumors.[2][3] A Phase III trial is planned for 2008. [edit] References 1. ^ Attard G, Belldegrun AS, de Bono JS (2005). "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer". BJU Int. 96 (9): 1241�6. doi:10.1111/j.1464-410X.2005.05821.x. PMID 16287438. 2. ^ "Hormone inhibitor promising for hard-to-treat prostate cancer". Press release. European Society for Medical Oncology (2007-07-08). Retrieved on 2008-07-22. 3. ^ Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS (2008). "Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven". Journal of Clinical Oncology 26. doi:10.1200/JCO.2007.15.9749.
|
Pages: 1 Prev: Very good news Next: Molecular Testing for Targeted Cancer Therapy |